The overall changes in the cholesterol panel with 20 mg of rosuvastatin and atorvastatin in the STARSHIP trial are shown in the current slide.

After 6 weeks, LDL-C was reduced by 50 % with rosuvastatin 20 mg compared to 42 % with atorvastatin 20 mg (P<.0001).  Similarly, non-HDL-C was reduced to a significantly greater extent with rosuvastatin 20 mg compared to atorvastatin 20 mg (45% versus 39 %; P<.01).1

No differences in HDL-C and TG were observed between the two agents.1

Reference:

1. Lloret, R et al.  Comparison of rosuvastatin versus atorvastatin in Hispanic-American patients with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology. 2006;98:768-773.